(LRCX) Lam Research - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5128073062
Stock:
Total Rating 89
Risk 83
Buy Signal 0.86
| Risk 5d forecast | |
|---|---|
| Volatility | 50.3% |
| Relative Tail Risk | -4.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.38 |
| Alpha | 160.43 |
| Character TTM | |
|---|---|
| Beta | 2.041 |
| Beta Downside | 2.423 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.10% |
| CAGR/Max DD | 1.50 |
EPS (Earnings per Share)
Revenue
Description: LRCX Lam Research
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits in the United States, China, Korea, Taiwan, Japan, Southeast Asia, and Europe. The company offers ALTUS systems to deposit conformal or selective films for tungsten or molybdenum metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SPEED gapfill high-density plasma chemical vapor deposition (CVD) products; Striker single-wafer atomic layer deposition products for dielectric film solutions; and VECTOR plasma-enhanced CVD products. It also provides Flex for dielectric etch applications; Vantex, a dielectric etch system that provides RF technology and repeatable wafer-to-wafer performance enabled by Equipment Intelligence solutions; Kiyo for conductor etch applications; Syndion for through-silicon via etch applications; and Versys metal products for metal etch processes. In addition, the company offers Coronus bevel clean products to enhance die yield; and Da Vinci, DV-Prime, EOS, and SP series products to address various wafer cleaning applications. Further, it provides Reliant deposition, etch, and clean products; and Sense.i platform products, as well as customer service, spares, and upgrades. Lam Research Corporation was incorporated in 1980 and is headquartered in Fremont, California.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income: 6.21b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 9.20 > 1.0 |
| NWC/Revenue: 37.96% < 20% (prev 50.97%; Δ -13.01% < -1%) |
| CFO/TA 0.33 > 3% & CFO 7.12b > Net Income 6.21b |
| Net Debt (-1.70b) to EBITDA (7.50b): -0.23 < 3 |
| Current Ratio: 2.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.27b) vs 12m ago -2.01% < -2% |
| Gross Margin: 49.80% > 18% (prev 0.48%; Δ 4933 % > 0.5%) |
| Asset Turnover: 99.73% > 50% (prev 81.70%; Δ 18.03% > 0%) |
| Interest Coverage Ratio: 41.06 > 6 (EBITDA TTM 7.50b / Interest Expense TTM 172.9m) |
Altman Z'' 10.00
| A: 0.36 (Total Current Assets 14.02b - Total Current Liabilities 6.21b) / Total Assets 21.39b |
| B: 1.47 (Retained Earnings 31.50b / Total Assets 21.39b) |
| C: 0.34 (EBIT TTM 7.10b / Avg Total Assets 20.62b) |
| D: 2.79 (Book Value of Equity 31.40b / Total Liabilities 11.25b) |
| Altman-Z'' Score: 12.44 = AAA |
Beneish M -2.99
| DSRI: 0.83 (Receivables 3.49b/3.30b, Revenue 20.56b/16.21b) |
| GMI: 0.96 (GM 49.80% / 47.60%) |
| AQI: 1.10 (AQ_t 0.22 / AQ_t-1 0.20) |
| SGI: 1.27 (Revenue 20.56b / 16.21b) |
| TATA: -0.04 (NI 6.21b - CFO 7.12b) / TA 21.39b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of LRCX shares?
As of February 28, 2026, the stock is trading at USD 233.89 with a total of 12,980,456 shares traded.
Over the past week, the price has changed by -4.50%, over one month by -1.92%, over three months by +50.18% and over the past year by +209.88%.
Over the past week, the price has changed by -4.50%, over one month by -1.92%, over three months by +50.18% and over the past year by +209.88%.
Is LRCX a buy, sell or hold?
Lam Research has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy LRCX.
- StrongBuy: 20
- Buy: 4
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LRCX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 274.7 | 17.5% |
| Analysts Target Price | 274.7 | 17.5% |
LRCX Fundamental Data Overview February 28, 2026
P/E Trailing = 48.9898
P/E Forward = 45.045
P/S = 14.6046
P/B = 29.4264
P/EG = 2.2026
Revenue TTM = 20.56b USD
EBIT TTM = 7.10b USD
EBITDA TTM = 7.50b USD
Long Term Debt = 3.73b USD (from longTermDebt, last quarter)
Short Term Debt = 754.0m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.70b USD (from netDebt column, last quarter)
Enterprise Value = 298.58b USD (300.28b + Debt 4.48b - CCE 6.18b)
Interest Coverage Ratio = 41.06 (Ebit TTM 7.10b / Interest Expense TTM 172.9m)
EV/FCF = 44.82x (Enterprise Value 298.58b / FCF TTM 6.66b)
FCF Yield = 2.23% (FCF TTM 6.66b / Enterprise Value 298.58b)
FCF Margin = 32.40% (FCF TTM 6.66b / Revenue TTM 20.56b)
Net Margin = 30.22% (Net Income TTM 6.21b / Revenue TTM 20.56b)
Gross Margin = 49.80% ((Revenue TTM 20.56b - Cost of Revenue TTM 10.32b) / Revenue TTM)
Gross Margin QoQ = 49.60% (prev 50.43%)
Tobins Q-Ratio = 13.96 (Enterprise Value 298.58b / Total Assets 21.39b)
Interest Expense / Debt = 0.95% (Interest Expense 42.5m / Debt 4.48b)
Taxrate = 13.21% (242.6m / 1.84b)
NOPAT = 6.16b (EBIT 7.10b * (1 - 13.21%))
Current Ratio = 2.26 (Total Current Assets 14.02b / Total Current Liabilities 6.21b)
Debt / Equity = 0.44 (Debt 4.48b / totalStockholderEquity, last quarter 10.15b)
Debt / EBITDA = -0.23 (Net Debt -1.70b / EBITDA 7.50b)
Debt / FCF = -0.25 (Net Debt -1.70b / FCF TTM 6.66b)
Total Stockholder Equity = 9.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.14% (Net Income 6.21b / Total Assets 21.39b)
RoE = 62.59% (Net Income TTM 6.21b / Total Stockholder Equity 9.93b)
RoCE = 51.98% (EBIT 7.10b / Capital Employed (Equity 9.93b + L.T.Debt 3.73b))
RoIC = 42.77% (NOPAT 6.16b / Invested Capital 14.41b)
WACC = 13.25% (E(300.28b)/V(304.76b) * Re(13.44%) + D(4.48b)/V(304.76b) * Rd(0.95%) * (1-Tc(0.13)))
Discount Rate = 13.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.17%
[DCF] Terminal Value 64.20% ; FCFF base≈5.74b ; Y1≈6.61b ; Y5≈9.29b
[DCF] Fair Price = 63.19 (EV 77.21b - Net Debt -1.70b = Equity 78.91b / Shares 1.25b; r=13.25% [WACC]; 5y FCF grow 17.85% → 2.90% )
EPS Correlation: 56.30 | EPS CAGR: 15.49% | SUE: 3.55 | # QB: 8
Revenue Correlation: 32.55 | Revenue CAGR: 7.60% | SUE: 2.67 | # QB: 6
EPS next Quarter (2026-03-31): EPS=1.35 | Chg7d=+0.000 | Chg30d=+0.152 | Revisions Net=+18 | Analysts=26
EPS current Year (2026-06-30): EPS=5.31 | Chg7d=+0.000 | Chg30d=+0.404 | Revisions Net=+30 | Growth EPS=+28.2% | Growth Revenue=+21.3%
EPS next Year (2027-06-30): EPS=6.89 | Chg7d=+0.004 | Chg30d=+0.973 | Revisions Net=+31 | Growth EPS=+29.8% | Growth Revenue=+23.0%
[Analyst] Revisions Ratio: +1.00 (18 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 11.4% (Discount Rate 13.4% - Earnings Yield 2.0%)
[Growth] Growth Spread = +9.7% (Analyst 21.1% - Implied 11.4%)
P/E Forward = 45.045
P/S = 14.6046
P/B = 29.4264
P/EG = 2.2026
Revenue TTM = 20.56b USD
EBIT TTM = 7.10b USD
EBITDA TTM = 7.50b USD
Long Term Debt = 3.73b USD (from longTermDebt, last quarter)
Short Term Debt = 754.0m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.70b USD (from netDebt column, last quarter)
Enterprise Value = 298.58b USD (300.28b + Debt 4.48b - CCE 6.18b)
Interest Coverage Ratio = 41.06 (Ebit TTM 7.10b / Interest Expense TTM 172.9m)
EV/FCF = 44.82x (Enterprise Value 298.58b / FCF TTM 6.66b)
FCF Yield = 2.23% (FCF TTM 6.66b / Enterprise Value 298.58b)
FCF Margin = 32.40% (FCF TTM 6.66b / Revenue TTM 20.56b)
Net Margin = 30.22% (Net Income TTM 6.21b / Revenue TTM 20.56b)
Gross Margin = 49.80% ((Revenue TTM 20.56b - Cost of Revenue TTM 10.32b) / Revenue TTM)
Gross Margin QoQ = 49.60% (prev 50.43%)
Tobins Q-Ratio = 13.96 (Enterprise Value 298.58b / Total Assets 21.39b)
Interest Expense / Debt = 0.95% (Interest Expense 42.5m / Debt 4.48b)
Taxrate = 13.21% (242.6m / 1.84b)
NOPAT = 6.16b (EBIT 7.10b * (1 - 13.21%))
Current Ratio = 2.26 (Total Current Assets 14.02b / Total Current Liabilities 6.21b)
Debt / Equity = 0.44 (Debt 4.48b / totalStockholderEquity, last quarter 10.15b)
Debt / EBITDA = -0.23 (Net Debt -1.70b / EBITDA 7.50b)
Debt / FCF = -0.25 (Net Debt -1.70b / FCF TTM 6.66b)
Total Stockholder Equity = 9.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.14% (Net Income 6.21b / Total Assets 21.39b)
RoE = 62.59% (Net Income TTM 6.21b / Total Stockholder Equity 9.93b)
RoCE = 51.98% (EBIT 7.10b / Capital Employed (Equity 9.93b + L.T.Debt 3.73b))
RoIC = 42.77% (NOPAT 6.16b / Invested Capital 14.41b)
WACC = 13.25% (E(300.28b)/V(304.76b) * Re(13.44%) + D(4.48b)/V(304.76b) * Rd(0.95%) * (1-Tc(0.13)))
Discount Rate = 13.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.17%
[DCF] Terminal Value 64.20% ; FCFF base≈5.74b ; Y1≈6.61b ; Y5≈9.29b
[DCF] Fair Price = 63.19 (EV 77.21b - Net Debt -1.70b = Equity 78.91b / Shares 1.25b; r=13.25% [WACC]; 5y FCF grow 17.85% → 2.90% )
EPS Correlation: 56.30 | EPS CAGR: 15.49% | SUE: 3.55 | # QB: 8
Revenue Correlation: 32.55 | Revenue CAGR: 7.60% | SUE: 2.67 | # QB: 6
EPS next Quarter (2026-03-31): EPS=1.35 | Chg7d=+0.000 | Chg30d=+0.152 | Revisions Net=+18 | Analysts=26
EPS current Year (2026-06-30): EPS=5.31 | Chg7d=+0.000 | Chg30d=+0.404 | Revisions Net=+30 | Growth EPS=+28.2% | Growth Revenue=+21.3%
EPS next Year (2027-06-30): EPS=6.89 | Chg7d=+0.004 | Chg30d=+0.973 | Revisions Net=+31 | Growth EPS=+29.8% | Growth Revenue=+23.0%
[Analyst] Revisions Ratio: +1.00 (18 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 11.4% (Discount Rate 13.4% - Earnings Yield 2.0%)
[Growth] Growth Spread = +9.7% (Analyst 21.1% - Implied 11.4%)